Current practice in transvenous lead extraction: a European Heart Rhythm Association EP Network Survey.

ELECTRa (European Lead Extraction ConTRolled) Registry--shedding light on transvenous lead extraction real-world practice in Europe. Herzschrittmacherther Elektrophysiol (2013) 0.80

Snare sheath versus evolution sheath in transvenous lead extraction. Int J Clin Exp Med (2015) 0.75

Lead Extraction of Cardiac Rhythm Devices: A Report of a Single-Center Experience. Front Cardiovasc Med (2017) 0.75

Forces applied during transvenous implantable cardioverter defibrillator lead removal. Biomed Res Int (2014) 0.75

Key Lessons from the ELECTRa Registry in the Modern Era of Transvenous Lead Extraction. Arrhythm Electrophysiol Rev (2017) 0.75

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J (2007) 4.15

2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace (2013) 4.07

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J (2015) 3.70

A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol (2009) 3.61

ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol (2003) 3.55

ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation (2003) 2.68

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace (2015) 2.66

Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace (2007) 2.58

Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol (2006) 2.56

Reduced right ventricular ejection fraction in endurance athletes presenting with ventricular arrhythmias: a quantitative angiographic assessment. Eur Heart J (2007) 2.45

Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J (2005) 2.39

2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J (2010) 2.36

Incidence and etiology of sports-related sudden cardiac death in Denmark--implications for preparticipation screening. Heart Rhythm (2010) 2.34

Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29

Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06

The European cardiac resynchronization therapy survey. Eur Heart J (2009) 2.04

How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. Europace (2014) 2.01

MitraClip® therapy in patients with end-stage systolic heart failure. Eur J Heart Fail (2011) 1.95

Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ (2012) 1.94

Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2010) 1.92

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

Nationwide study of sudden cardiac death in persons aged 1-35 years. Eur Heart J (2010) 1.87

HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm (2008) 1.79

Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol (2008) 1.79

Echocardiographic quantification of left ventricular asynchrony predicts an acute hemodynamic benefit of cardiac resynchronization therapy. J Am Coll Cardiol (2002) 1.77

HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace (2008) 1.70

Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace (2008) 1.68

The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases. J Cardiovasc Electrophysiol (2012) 1.65

Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. Europace (2011) 1.64

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) (2014) 1.61

Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60

Plasma YKL-40, a new biomarker for atrial fibrillation? Europace (2009) 1.59

Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol (2005) 1.55

Deep sedation for catheter ablation of atrial fibrillation: a prospective study in 650 consecutive patients. J Cardiovasc Electrophysiol (2011) 1.55

2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm (2012) 1.54

Multicenter experience with transvenous lead extraction of active fixation coronary sinus leads. Pacing Clin Electrophysiol (2012) 1.54

Low disease prevalence and inappropriate implantable cardioverter defibrillator shock rate in Brugada syndrome: a nationwide study. Europace (2012) 1.53

Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm (2012) 1.53

Current practice of ventricular tachycardia ablation in patients with implantable cardioverter-defibrillators. Europace (2012) 1.52

Variability of coronary venous anatomy in patients undergoing cardiac resynchronization therapy: a high-speed rotational venography study. Heart Rhythm (2007) 1.50

Recurrent vasovagal syncope: comparison between clomipramine and nitroglycerin as drug challenges during head-up tilt testing. Eur Heart J (2009) 1.48

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace (2007) 1.46

2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace (2012) 1.46

Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure. Eur Heart J (2006) 1.46

2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace (2010) 1.45

Fluoroscopic left ventricular lead position and the long-term clinical outcome of cardiac resynchronization therapy. Pacing Clin Electrophysiol (2011) 1.44

2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail (2010) 1.43

Sodium current and potassium transient outward current genes in Brugada syndrome: screening and bioinformatics. Can J Cardiol (2012) 1.43

Feasibility and acute efficacy of radiofrequency ablation of cavotricuspid isthmus-dependent atrial flutter guided by real-time 3D TEE. JACC Cardiovasc Imaging (2011) 1.42

Comparison of effects on coagulation and inflammatory markers using a duty-cycled bipolar and unipolar radiofrequency pulmonary vein ablation catheter vs. a cryoballoon catheter for pulmonary vein isolation. Europace (2013) 1.41

Cardiac resynchronization therapy for heart failure shows great promise. Isr Med Assoc J (2003) 1.41

The role of premature atrial contractions as the main triggers of postoperative atrial fibrillation. J Electrocardiol (2005) 1.40

Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts. J Cardiovasc Pharmacol (2014) 1.39

2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Rev Esp Cardiol (Engl Ed) (2016) 1.39

KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval. Heart Rhythm (2007) 1.39

The effectiveness of a high output/short duration radiofrequency current application technique in segmental pulmonary vein isolation for atrial fibrillation. Europace (2006) 1.38

Anatomy of pulmonary veins by real-time 3D TEE: implications for catheter-based pulmonary vein ablation. JACC Cardiovasc Imaging (2012) 1.38

What are the costs of heart failure? Europace (2011) 1.36

Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol (2009) 1.32

Adenosine testing after second-generation balloon devices (cryothermal and laser) mediated pulmonary vein ablation for atrial fibrillation. J Interv Card Electrophysiol (2014) 1.29

Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol (2005) 1.26

Acute effects of cardiac resynchronization therapy on left ventricular Doppler indices in patients with congestive heart failure. Am Heart J (2002) 1.25

Impact of hybrid procedure on P wave duration for atrial fibrillation ablation. J Interv Card Electrophysiol (2015) 1.24

SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. Heart Rhythm (2011) 1.21

Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc Imaging (2013) 1.20

Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail (2010) 1.20

ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace (2012) 1.18

Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study. Circ Arrhythm Electrophysiol (2011) 1.16

Minimal invasive surgery for atrial fibrillation: an updated review. Europace (2012) 1.16

Coronary sinus visualization by 3-dimensional real-time echocardiography. J Am Soc Echocardiogr (2007) 1.16

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace (2013) 1.16

:Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. Int J Cardiol (2008) 1.15

Timing and magnitude of regional right ventricular function: a speckle tracking-derived strain study of normal subjects and patients with right ventricular dysfunction. J Am Soc Echocardiogr (2010) 1.14

Evaluation of the left atrial appendage with real-time 3-dimensional transesophageal echocardiography: implications for catheter-based left atrial appendage closure. Circ Cardiovasc Imaging (2011) 1.14

Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 1.11

A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovasc Res (2013) 1.11

KCNE3 mutation V17M identified in a patient with lone atrial fibrillation. Cell Physiol Biochem (2008) 1.09

J-shaped association between QTc interval duration and the risk of atrial fibrillation: results from the Copenhagen ECG study. J Am Coll Cardiol (2013) 1.08

The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail (2011) 1.06

Relation of 97T polymorphism in KCNE5 to risk of atrial fibrillation. Am J Cardiol (2005) 1.06

Atrial and ventricular volume and function evaluated by magnetic resonance imaging in patients with persistent atrial fibrillation before and after cardioversion. Am J Cardiol (2006) 1.06

A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias. Can J Cardiol (2011) 1.05

Epicardial off-pump pulmonary vein isolation and vagal denervation improve long-term outcome and quality of life in patients with atrial fibrillation. J Thorac Cardiovasc Surg (2009) 1.04

Risk of atrial fibrillation as a function of the electrocardiographic PR interval: results from the Copenhagen ECG Study. Heart Rhythm (2013) 1.03

Echocardiographic parameters of mechanical synchrony in healthy individuals. Am J Cardiol (2008) 1.03

The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J (2009) 1.02

Comparison of a non-invasive arterial pulse contour technique and echo Doppler aorta velocity-time integral on stroke volume changes in optimization of cardiac resynchronization therapy. Europace (2010) 1.02

Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail (2008) 1.01

Myocardial infarction does not preclude electrical and hemodynamic benefits of cardiac resynchronization therapy in dyssynchronous canine hearts. Circ Arrhythm Electrophysiol (2010) 1.01

Left ventricular endocardial pacing improves resynchronization therapy in canine left bundle-branch hearts. Circ Arrhythm Electrophysiol (2009) 1.01

Atrial secretion of B-type natriuretic peptide. Eur Heart J (2006) 1.00

The European CRT Survey: 1 year (9-15 months) follow-up results. Eur J Heart Fail (2012) 0.99

Surgical Ablation for Atrial Fibrillation. N Engl J Med (2015) 0.99

Characterizations of a loss-of-function mutation in the Kir3.4 channel subunit. Biochem Biophys Res Commun (2007) 0.96

Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol (2008) 0.96

EnSite Velocity cardiac mapping system: a new platform for 3D mapping of cardiac arrhythmias. Expert Rev Med Devices (2010) 0.95